Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies - Tabular View

Tracking Information
First Received Date ^ICMJE	June 5, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE	April 2001
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00038883 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Official Title ^ICMJE	Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Brief Summary	High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Detailed Description
Study Phase
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Condition ^ICMJE	Leukemia, Lymphocytic, Chronic Leukemia, Lymphocytic, Acute Lymphoma, Low-Grade Lymphoma, T-Cell Lymphoma, B-Cell
Intervention ^ICMJE	Drug: Campath-1H
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Terminated
Enrollment ^ICMJE	142
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Patients with CLL, ALL, low grade Lymphoma, B and T cell Lymphoma of the intermediate and high grade (if not eligible for autologous transplant) CD52 expression of >20% by flow cytometry. Patients in relapse after conventional treatment. Patients with an HLA-identical or one-antigen mismatched sibling, or matched unrelated donor. Patients previously exposed to Campath-1H treatment response. Patient must be at least 2 months or later from the last dose of Campath-1H.
Gender	Both
Ages	15 Years to 60 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00038883
Responsible Party
Study ID Numbers ^ICMJE	ID99-410
Study Sponsor ^ICMJE	M.D. Anderson Cancer Center
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	M.D. Anderson Cancer Center
Verification Date	January 2005
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP